Reinsurance Group of America, Incorporated (RGA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights strong financial metrics, capital flexibility, and shareholder return plans, which are positive indicators. The Q&A section reveals normal volatility in claims and deployable excess capital. While guidance remains unchanged, the company anticipates future profitability and market expansion, suggesting optimism. The lack of new partnerships or secondary offerings, and the absence of guidance refusal, further supports a positive outlook. Therefore, considering all factors, the stock price is likely to experience a positive movement of 2% to 8% over the next two weeks.
Key Financial Performance
Operating EPS $6.37 per share, a record high, with strong performance in Asia Traditional, EMEA, and U.S. Financial Solutions. Reasons include successful execution of strategy and positive contributions from the Equitable transaction.
Traditional Business Premiums Up 8.5% year-to-date on a constant currency basis, driven by strong growth in the U.S., EMEA, and APAC regions. This reflects ongoing vitality and strong momentum.
Capital Deployment $2.4 billion deployed year-to-date, including $1.5 billion into the Equitable transaction and $900 million into over 20 other transactions globally. These transactions leverage client relationships and biometric risk expertise.
Value of In-Force Business Margins Increased by 16% over the past 3 quarters, indicating success in creating long-term value through new business and management actions.
Pretax Adjusted Operating Income $534 million for the quarter, or $6.37 per share after tax. This reflects strong results and above expectations, with notable strength in Asia Traditional, EMEA, and U.S. Financial Solutions.
Effective Tax Rate 19.6% for the quarter, below the expected range of 23%-24%, primarily due to the jurisdictional mix of earnings.
Economic Claims Experience Favorable by $5 million in the quarter, driven by APAC and Canada, partially offset by the U.S. Traditional segment. However, the current period financial impact was unfavorable by $50 million.
Share Repurchases $75 million repurchased during the quarter at an average price of $184.58 per share, reflecting a balanced approach to capital deployment.
Book Value Per Share Increased to $159.83, representing a compounded annual growth rate of 9.7% since the beginning of 2021.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Strategic Underwriting Program: Enhanced with a digital solution, enabling exclusive partnership with a key client with a strong brand and large distribution footprint.
Critical Illness Combination Product: Co-developed a first-of-its-kind product in Mainland China, leveraging regulatory changes, with strong early sales performance.
Second-Generation Cancer Treatment Product: Launched in Korea, building on the success of the previous version, with over 1 million policies sold.
Asia Pacific Market: Strong performance in traditional business, with innovative solutions and strategic partnerships in Hong Kong, Mainland China, and Korea.
EMEA Market: Closed multiple transactions, including a market-first in Switzerland, showcasing growth in asset-intensive reinsurance.
Capital Deployment: Deployed $2.4 billion year-to-date, including $1.5 billion into the Equitable transaction and $900 million into over 20 global transactions.
Share Repurchases: Repurchased $75 million of common shares during the quarter.
Portfolio Repositioning: Progressed 75% on asset portfolio repositioning related to the Equitable transaction, with completion expected in 6-9 months.
Ruby Re Utilization: Advanced retrocession of U.S. PRT business to Ruby Re, with full deployment expected by mid-2026.
Value of In-Force Business Margins: Increased by 16% over the past 3 quarters, reflecting efforts to create long-term value through new business and management actions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Economic claims experience: Unfavorable financial impact of $50 million in the quarter, driven by modestly unfavorable claims experience in U.S. individual life and group segments.
Variable investment income: Lower variable investment income negatively impacted financial results, particularly in U.S. Financial Solutions and Corporate segments.
Portfolio repositioning: Repositioning of the Equitable transaction asset portfolio is only 75% complete, with remaining adjustments expected over the next 6 to 9 months, posing potential execution risks.
Group business repricing: U.S. group business remains breakeven and is not expected to fully stabilize until January 2026, indicating ongoing challenges in this segment.
General expenses: Higher general expenses contributed to an unfavorable adjusted operating loss in the Corporate and Other segment.
Real estate joint ventures: Lower activity in real estate joint ventures resulted in a $40 million shortfall in variable investment income.
Regulatory changes in China: Recent regulatory changes in Mainland China allow new products, but navigating these changes could pose operational and compliance challenges.
Capital deployment: Significant capital deployment of $2.4 billion year-to-date, including $1.5 billion into the Equitable transaction, could strain financial flexibility if not managed carefully.
Tax rate variability: Quarterly tax rate of 19.6% was below the expected range, but full-year tax rate is expected to normalize, indicating potential variability in tax obligations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue and Earnings Projections: The Equitable transaction is expected to contribute around $70 million of pretax income for the full year 2025, increasing to $160 million to $170 million in 2026, and approximately $200 million per year by 2027. The value of in-force business margins increased by 16% over the past 3 quarters, indicating long-term earnings growth potential.
Portfolio Repositioning: The asset portfolio repositioning related to the Equitable transaction is approximately 75% complete and is expected to be finalized within the next 6 to 9 months.
Capital Deployment: Year-to-date, $2.4 billion of capital has been deployed, including $1.5 billion into the Equitable transaction and $900 million into over 20 other transactions globally. The company plans to continue balancing capital deployment into the business with shareholder returns.
New Business Pipeline: The new business pipeline remains strong across all regions, with a focus on selecting opportunities based on expected returns, risk appetite, and strategic considerations. The company expects continued growth in new business and repeat transactions.
Tax Rate Outlook: The effective tax rate for the full year 2025 is expected to be in the range of 23% to 24%.
Shareholder Returns: The company intends to return 20% to 30% of after-tax operating earnings to shareholders through dividends and share repurchases over the long term.
Ruby Re Deployment: The Ruby Re retrocession vehicle is expected to be fully deployed by mid-2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Quarterly dividends: The company intends to continue returning capital to shareholders through quarterly dividends.
Long-term shareholder return: Over the longer term, the company expects total shareholder return of capital through dividends and share repurchases to range between 20% to 30% of after-tax operating earnings on average.
Share repurchase in Q3 2025: The company repurchased $75 million of common shares during the quarter at an average price of $184.58.
Opportunistic share repurchases: The company plans to be opportunistic with share repurchases quarter-by-quarter, depending on capital position, transaction pipeline, and valuation metrics.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What was the U.S. claims activity in Traditional in the quarter?
A:The U.S. Traditional segment experienced about $30 million of negative claims experience on the individual life side, which was considered normal volatility and below a standard deviation. On the group side, there was a $20 million negative experience, consistent with expectations.
Q:Were there any onetime items that impacted premiums in the U.S. Traditional segment?
A:Yes, there was an in-force action involving the recapture of a treaty, which resulted in a $20 million positive impact to results but reduced recorded premiums from that treaty.
Q:How soon would it make sense to recognize the mortality reduction benefit from GLP-1 drugs?
A:The company has not made material changes to assumptions due to anti-obesity medication but believes these drugs will have a meaningful benefit on population-level mortality. Their analysis aligns with Swiss Re's central estimate, though the numbers quoted in the question were on the high end of the estimate.
Q:What is the expected lift to the annual run rate from the actual assumptions update?
A:The $600 million long-term value impact will increase the annual run rate by $15 million next year, gradually ramping up to a $25 million increase by 2040.
Q:What type of liabilities is Ruby Re considering for its structure?
A:Ruby Re focuses on relatively simple liabilities, such as pension risk transfer and other asset-intensive transactions. The company plans to explore new vehicles for potentially broader liability types but will remain within areas of expertise.
Q:How far along is the company in executing in-force actions, and what opportunities remain?
A:The company has achieved about $45 million of cumulative in-force actions year-to-date, consistent with the $50 million annual target. Opportunities for in-force management actions remain across the globe, leveraging strong client partnerships.
Q:Is the value in-force benefit to excess capital fully deployable into growth?
A:Yes, the value in-force capital is real and deployable into transactions. It is recognized under rating agency frameworks with significant haircuts and amortizes over time. The company has sufficient liquidity and leverage ratios to deploy this capital.
Q:What is the impact of the U.K. mortality assumption review?
A:The review increased expectations for future U.K. mortality, leading to higher future mortality claims and lower future longevity claims. The net economic effect is neutral due to the balanced book of business.
Q:What is the accounting smoothing expectation for the Equitable block?
A:Approximately 50% of the Equitable block will benefit from accounting smoothing of results over time.
Q:What is the trajectory of the group headwind from the medical piece?
A:The group business is short-term and will be fully repriced by January 2026, with expectations of profitability for all segments thereafter.
Q:Is RGA becoming more competitive or aggressive in accepting lower IRRs to win business?
A:Management stated there has been no change in risk tolerance, processes, or culture. The company focuses on exclusive transactions that align with its expertise and avoids tendered business outside its sweet spot.
Q:Why does LDTI not seem to provide the expected smoothing benefit?
A:LDTI provides some smoothing, but capped cohorts, which represent about 15% of the business, result in more immediate recognition of negative impacts. These cohorts are closely monitored for in-force actions.
Q:Has the economic solvency regulation in Japan created opportunities for RGA?
A:Yes, the regulation has driven increased activity in Japan, particularly in coinsurance of blocks with biometric and asset risks. RGA remains selective in pursuing opportunities.
Q:What is the sustainable earnings power of RGA based on recent results?
A:The strong quarterly results reflect capital deployment and portfolio repositioning, including the Equitable transaction. Management suggests looking at year-to-date results for a better gauge of sustainable earnings power.
Q:Has RGA considered partnerships with alternative managers for asset-intensive business?
A:RGA uses external relationships for private assets where it lacks scale but does not compete on pure asset transactions. It focuses on blocks with biometric risks and long-standing client relationships.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing whether LDTI provides the expected smoothing benefit, offering only general comments about capped cohorts and monitoring. Additionally, the response to whether RGA is becoming more aggressive in accepting lower IRRs was somewhat vague, emphasizing culture and strategy without directly addressing the concern.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
America target
Award solution
Belgium market
China change
Conference
Continental Europe
Creation approach
EMEA region
Europe asset
Federation Insurers
Insurers Outstanding
Kong Federation
Kong RGA
Kong addition
Kong solution
Korea RGA
North America
Outstanding Reinsurance
President Investor
RGA illness
RGA market
RGA portion
RGA promise
RGA result
RGA year
Reinsurance Scheme
Relations course
Results line
Senior Vice
Vice President
advantage
combination
globe
highlight
market leader
product client
transaction capital
underwriting capability
win
RGA Transcript
Reinsurance Group of America, Incorporated (RGA) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary shows strong financial performance with significant year-over-year growth in revenue, net income, operating income, and EPS. Investment income also saw a notable increase, and ROE improved, suggesting efficient capital management. Although operational updates, strategic initiatives, risk, and return were not discussed, the financial metrics alone indicate a positive outlook. The lack of additional insights from the Q&A doesn't significantly impact this positive sentiment.
Saputo Inc. (SAP:CA) Q3 2026 Earnings Call Transcript
Positive2-6
The earnings call summary and Q&A indicate a positive outlook. Strong financial metrics, such as a significant increase in in-force business margins and a well-progressed portfolio repositioning, suggest long-term growth. The positive sentiment is reinforced by a robust new business pipeline, strategic capital deployment, and a clear shareholder return plan. While there are some uncertainties in the Q&A, the overall strategic plan and optimistic guidance outweigh these concerns, suggesting a positive stock price movement.
Reinsurance Group of America, Incorporated (RGA) Q4 2025 Earnings Call Transcript
Positive2-6
The earnings call summary indicates strong financial performance with a 7.4% premium growth, increased book value, and better-than-expected variable investment income. The Q&A highlights strategic moves like exiting the U.S. health care business and focusing on high-return areas, with positive guidance for 2026. Although there are concerns about management's lack of specificity, the overall sentiment is positive due to optimistic EPS growth targets, shareholder returns, and strategic capital deployment. The absence of a market cap suggests a likely moderate stock price reaction, leading to a 'Positive' sentiment rating.
Reinsurance Group of America, Incorporated (RGA) Q3 2025 Earnings Call Transcript
Positive10-31
The earnings call summary highlights strong financial metrics, capital flexibility, and shareholder return plans, which are positive indicators. The Q&A section reveals normal volatility in claims and deployable excess capital. While guidance remains unchanged, the company anticipates future profitability and market expansion, suggesting optimism. The lack of new partnerships or secondary offerings, and the absence of guidance refusal, further supports a positive outlook. Therefore, considering all factors, the stock price is likely to experience a positive movement of 2% to 8% over the next two weeks.
RGA Slides
RGA Q1 2026 slides: earnings beat forecasts, ROE hits 16.2%2026-05-07
RGA Q4 2025 slides: Record earnings drive stock surge as capital position strengthens2026-02-05
RGA Q2 2025 slides: EPS misses estimates despite 11% premium growth2025-10-30
RGA Q2 2025 slides: EPS declines to $4.72 amid strong premium growth2025-07-31
RGA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
